Journal article 1075 views 370 downloads
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study
Seizure, Volume: 91, Pages: 159 - 166
Swansea University Author:
Owen Pickrell
-
PDF | Version of Record
© 2021 The Authors. This is an open access article under the CC BY-NC-ND license
Download (1.03MB)
DOI (Published version): 10.1016/j.seizure.2021.05.025
Abstract
Purpose: To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in primary and secondary care in the UK.Methods: Patients with confirmed LGS were anonymously i...
| Published in: | Seizure |
|---|---|
| ISSN: | 1059-1311 |
| Published: |
Elsevier BV
2021
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa57199 |
| first_indexed |
2021-06-24T09:21:59Z |
|---|---|
| last_indexed |
2021-07-15T03:24:00Z |
| id |
cronfa57199 |
| recordtype |
SURis |
| fullrecord |
<?xml version="1.0"?><rfc1807><datestamp>2021-07-14T16:17:31.9566382</datestamp><bib-version>v2</bib-version><id>57199</id><entry>2021-06-24</entry><title>Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study</title><swanseaauthors><author><sid>1c3044b5ff7a6552ff5e8c9e3901c807</sid><ORCID>0000-0003-4396-5657</ORCID><firstname>Owen</firstname><surname>Pickrell</surname><name>Owen Pickrell</name><active>true</active><ethesisStudent>false</ethesisStudent></author></swanseaauthors><date>2021-06-24</date><deptcode>MEDS</deptcode><abstract>Purpose: To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in primary and secondary care in the UK.Methods: Patients with confirmed LGS were anonymously identified from the UK Clinical Practice Research Datalink (CPRD) GOLD database (01/01/1987–31/10/2018) using the LGS Read Code (F250500). Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients enrolled in CPRD GOLD and alive in 2017. CPRD data were linked to HES to calculate HCRU, and to the Office for National Statistics mortality registry.Results: Period prevalence of LGS was 0.578/10,000 (n = 180), with 74 and 106 patients identified with confirmed (0.289/10,000) and probable LGS (0.420/10,000). Mean (max) ASM usage was ~1 (3) per year. In confirmed LGS, valproate (72%), lamotrigine (69%), and clobazam (66%) were the most commonly prescribed ASMs. HCRU (per patient-year) was similar in confirmed and probable LGS and mostly consisted of primary care general practitioner consultations (4–6), outpatient visits (5–10), inpatient admissions (1–4), and A&E visits (1). During the follow-up period, 18 patients died with crude mortality rates of 6.12 (confirmed LGS) and 4.17 (probable LGS) deaths per 1000 person-years.Conclusion: Prevalence of LGS appears low in the UK. The similarly high HCRU and mortality rates in confirmed and probable LGS support the validity and specificity of the probable LGS algorithm and high burden of LGS.</abstract><type>Journal Article</type><journal>Seizure</journal><volume>91</volume><journalNumber/><paginationStart>159</paginationStart><paginationEnd>166</paginationEnd><publisher>Elsevier BV</publisher><placeOfPublication/><isbnPrint/><isbnElectronic/><issnPrint>1059-1311</issnPrint><issnElectronic/><keywords>Read Code; Healthcare resource utilization; Lennox-Gastaut syndrome; Antiseizure medication; Clinical Practice Research Datalink; Prevalence</keywords><publishedDay>1</publishedDay><publishedMonth>10</publishedMonth><publishedYear>2021</publishedYear><publishedDate>2021-10-01</publishedDate><doi>10.1016/j.seizure.2021.05.025</doi><url/><notes/><college>COLLEGE NANME</college><department>Medical School</department><CollegeCode>COLLEGE CODE</CollegeCode><DepartmentCode>MEDS</DepartmentCode><institution>Swansea University</institution><apcterm>Other</apcterm><lastEdited>2021-07-14T16:17:31.9566382</lastEdited><Created>2021-06-24T10:20:13.3630963</Created><path><level id="1">Faculty of Medicine, Health and Life Sciences</level><level id="2">Swansea University Medical School - Medicine</level></path><authors><author><firstname>Richard F.M.</firstname><surname>Chin</surname><order>1</order></author><author><firstname>Owen</firstname><surname>Pickrell</surname><orcid>0000-0003-4396-5657</orcid><order>2</order></author><author><firstname>Florent</firstname><surname>Guelfucci</surname><order>3</order></author><author><firstname>Monique</firstname><surname>Martin</surname><order>4</order></author><author><firstname>Rowena</firstname><surname>Holland</surname><order>5</order></author></authors><documents><document><filename>57199__20401__bf5423a61a994857a337df941eb8c562.pdf</filename><originalFilename>57199.pdf</originalFilename><uploaded>2021-07-14T16:16:06.7240410</uploaded><type>Output</type><contentLength>1078445</contentLength><contentType>application/pdf</contentType><version>Version of Record</version><cronfaStatus>true</cronfaStatus><documentNotes>© 2021 The Authors. This is an open access article under the CC BY-NC-ND license</documentNotes><copyrightCorrect>true</copyrightCorrect><language>eng</language><licence>http://creativecommons.org/licenses/by-nc-nd/4.0/</licence></document></documents><OutputDurs/></rfc1807> |
| spelling |
2021-07-14T16:17:31.9566382 v2 57199 2021-06-24 Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study 1c3044b5ff7a6552ff5e8c9e3901c807 0000-0003-4396-5657 Owen Pickrell Owen Pickrell true false 2021-06-24 MEDS Purpose: To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in primary and secondary care in the UK.Methods: Patients with confirmed LGS were anonymously identified from the UK Clinical Practice Research Datalink (CPRD) GOLD database (01/01/1987–31/10/2018) using the LGS Read Code (F250500). Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients enrolled in CPRD GOLD and alive in 2017. CPRD data were linked to HES to calculate HCRU, and to the Office for National Statistics mortality registry.Results: Period prevalence of LGS was 0.578/10,000 (n = 180), with 74 and 106 patients identified with confirmed (0.289/10,000) and probable LGS (0.420/10,000). Mean (max) ASM usage was ~1 (3) per year. In confirmed LGS, valproate (72%), lamotrigine (69%), and clobazam (66%) were the most commonly prescribed ASMs. HCRU (per patient-year) was similar in confirmed and probable LGS and mostly consisted of primary care general practitioner consultations (4–6), outpatient visits (5–10), inpatient admissions (1–4), and A&E visits (1). During the follow-up period, 18 patients died with crude mortality rates of 6.12 (confirmed LGS) and 4.17 (probable LGS) deaths per 1000 person-years.Conclusion: Prevalence of LGS appears low in the UK. The similarly high HCRU and mortality rates in confirmed and probable LGS support the validity and specificity of the probable LGS algorithm and high burden of LGS. Journal Article Seizure 91 159 166 Elsevier BV 1059-1311 Read Code; Healthcare resource utilization; Lennox-Gastaut syndrome; Antiseizure medication; Clinical Practice Research Datalink; Prevalence 1 10 2021 2021-10-01 10.1016/j.seizure.2021.05.025 COLLEGE NANME Medical School COLLEGE CODE MEDS Swansea University Other 2021-07-14T16:17:31.9566382 2021-06-24T10:20:13.3630963 Faculty of Medicine, Health and Life Sciences Swansea University Medical School - Medicine Richard F.M. Chin 1 Owen Pickrell 0000-0003-4396-5657 2 Florent Guelfucci 3 Monique Martin 4 Rowena Holland 5 57199__20401__bf5423a61a994857a337df941eb8c562.pdf 57199.pdf 2021-07-14T16:16:06.7240410 Output 1078445 application/pdf Version of Record true © 2021 The Authors. This is an open access article under the CC BY-NC-ND license true eng http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| title |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| spellingShingle |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study Owen Pickrell |
| title_short |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| title_full |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| title_fullStr |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| title_full_unstemmed |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| title_sort |
Prevalence, healthcare resource utilization and mortality of Lennox-Gastaut syndrome: retrospective linkage cohort study |
| author_id_str_mv |
1c3044b5ff7a6552ff5e8c9e3901c807 |
| author_id_fullname_str_mv |
1c3044b5ff7a6552ff5e8c9e3901c807_***_Owen Pickrell |
| author |
Owen Pickrell |
| author2 |
Richard F.M. Chin Owen Pickrell Florent Guelfucci Monique Martin Rowena Holland |
| format |
Journal article |
| container_title |
Seizure |
| container_volume |
91 |
| container_start_page |
159 |
| publishDate |
2021 |
| institution |
Swansea University |
| issn |
1059-1311 |
| doi_str_mv |
10.1016/j.seizure.2021.05.025 |
| publisher |
Elsevier BV |
| college_str |
Faculty of Medicine, Health and Life Sciences |
| hierarchytype |
|
| hierarchy_top_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_top_title |
Faculty of Medicine, Health and Life Sciences |
| hierarchy_parent_id |
facultyofmedicinehealthandlifesciences |
| hierarchy_parent_title |
Faculty of Medicine, Health and Life Sciences |
| department_str |
Swansea University Medical School - Medicine{{{_:::_}}}Faculty of Medicine, Health and Life Sciences{{{_:::_}}}Swansea University Medical School - Medicine |
| document_store_str |
1 |
| active_str |
0 |
| description |
Purpose: To retrospectively investigate the prevalence, demography, antiseizure medication (ASM) usage, healthcare resource utilization (HCRU), and mortality of patients with Lennox-Gastaut syndrome (LGS) in primary and secondary care in the UK.Methods: Patients with confirmed LGS were anonymously identified from the UK Clinical Practice Research Datalink (CPRD) GOLD database (01/01/1987–31/10/2018) using the LGS Read Code (F250500). Probable LGS was identified using the International Classification of Diseases-10/Read Code for epilepsy (Hospital Episode Statistics [HES]/CPRD) plus rufinamide prescription. Period prevalence was calculated based on patients enrolled in CPRD GOLD and alive in 2017. CPRD data were linked to HES to calculate HCRU, and to the Office for National Statistics mortality registry.Results: Period prevalence of LGS was 0.578/10,000 (n = 180), with 74 and 106 patients identified with confirmed (0.289/10,000) and probable LGS (0.420/10,000). Mean (max) ASM usage was ~1 (3) per year. In confirmed LGS, valproate (72%), lamotrigine (69%), and clobazam (66%) were the most commonly prescribed ASMs. HCRU (per patient-year) was similar in confirmed and probable LGS and mostly consisted of primary care general practitioner consultations (4–6), outpatient visits (5–10), inpatient admissions (1–4), and A&E visits (1). During the follow-up period, 18 patients died with crude mortality rates of 6.12 (confirmed LGS) and 4.17 (probable LGS) deaths per 1000 person-years.Conclusion: Prevalence of LGS appears low in the UK. The similarly high HCRU and mortality rates in confirmed and probable LGS support the validity and specificity of the probable LGS algorithm and high burden of LGS. |
| published_date |
2021-10-01T04:51:59Z |
| _version_ |
1851639170144927744 |
| score |
11.090009 |

